利妥昔单抗联合CHOP治疗弥漫大B细胞性非霍奇金淋巴瘤的临床观察  

A Clinical Study of Rituximab Combined with CHOP in Treatment of B Cell Non-Hodgkins Lymphoma

作　　者：李岭[1] 李志铭[2] 

机构地区：[1]南华大学第二附属医院血液内科,湖南衡阳421001 [2]中山大学肿瘤防治中心内科,广东广州510060

出　　处：《肿瘤基础与临床》2009年第1期36-37,共2页journal of basic and clinical oncology

摘　　要：目的比较利妥昔单抗联合CHOP方案和单用CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效和毒副反应。方法将26例B细胞性非霍奇金淋巴瘤(NHL)分为两组,一组采用利妥昔单抗联合CHOP方案,利妥昔单抗用量为375mg/m2,每个疗程的第1天使用;另一组单用CHOP方案。结果利妥昔单抗联合化疗组的完全缓解率(CR)46.2%,总有效率(OR)76.9%;CHOP组CR率38.5%,OR率61.5%,两组疗效比较差异有统计学意义。治疗后的毒副反应比较差异无统计学意义。结论利妥昔单抗和CHOP方案联用能明显提高B细胞NHL患者的CR率和OR率,未增加毒副反应,有望成为B细胞NHL的一线治疗方案。Objective To compare the efficacy of Rituximab plus CHOP and CHOP alone on diagnosed patients with B-cell non-Hodgkius lymphoma（NHL） , and to analyze toxicities. Methods A total of 26 diagnosed patients with B-cell NHL were divided into 2 groups. The 13 cases in the Rituximab group were administered by Rituximab （375 mg/m^2 , day 1 ） combine with CHOP regimen. The remaining 13 cases in the CHOP group were treated with CHOP regimen only. Results The complete remission （CR） rate and total response（OR） rate in the Rituximab group were 46.2% and 76.9% respectively, while the corresponding rates in the CHOP group were 38.5% and 61.5% respectively. The therapeutic efficacy differences between the two groups showed statistical significance. The toxicities of the treatment had no statistical significance. Conclusion Rituximab can increase the therapeutic efficacy of CHOP regimen on diagnosed patients with B-cell NHL, without a clinically significant increase in toxicity. Rituximab combined with CHOP regimen can be the first choice in the treatment of B-cell NHL.

关 键 词：利妥昔单抗 非霍奇金淋巴瘤 化疗 

分 类 号：R733.1[医药卫生—肿瘤]